SyntekaBio KRX:226330KOSDAQ
신테카바이오 · Korean news coverage and regulatory filings, organized.
Articles, 24h1
Articles, 7 days1
DART filings, 7 days0
Articles tracked26since Sep 11
In Q2 2026, SyntekaBio reported revenue of ₩449m, up 29.9% year on year, and an operating loss of ₩2.2bn. SyntekaBio (신테카바이오) appeared in 1 Korean news article and 0 DART filings over the past seven days. Coverage peaked on Oct 21 with 5 articles.
Filing signals Control change 4 quarters of losses Screener
SyntekaBio quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩449m | +29.9% | −₩2.2bn | −₩2.2bn |
| Q1 2026 | ₩422m | -51.4% | −₩3.5bn | −₩3.5bn |
| Q4 2025 derived | ₩1.8bn | +1453.9% | −₩2.5bn margin −141.5% | −₩4.0bn |
| Q3 2025 | ₩455m | +79321.2% | −₩2.3bn | −₩2.3bn |
| Q2 2025 | ₩346m | +38336.0% | −₩3.0bn | −₩3.8bn |
| Q1 2025 | ₩869m | +13881.7% | −₩3.0bn | −₩7.3bn |
| Q4 2024 derived | ₩113m | -1.3% | −₩3.6bn | −₩4.3bn |
| Q3 2024 | ₩1m | -78.1% | −₩3.9bn | −₩2.7bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
SyntekaBio top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
Latest SyntekaBio news Korean headlines
-
신테카바이오, '경영혁신위' 신설…내부통제·경영쇄신 본격화
1 more on this story · 1 outlets
- 신테카바이오, 경영혁신위 신설…재감사·내부통제 강화한스경제 · Oct 21 15:50
-
신테카바이오, 한국형 ARPA-H 공동연구기관 선정…AI로 비마약성 진통제 발굴
1 more on this story · 1 outlets
- [더벨]신테카바이오, ‘한국형 ARPA-H 프로젝트’ 공동연구기관 선정머니투데이 · Oct 6 09:18
-
신테카바이오, 임원 대여금 회수 완료… 감사인과 재감사 일정 착수
1 more on this story · 1 outlets
- 신테카바이오, 임원 대여금 회수…재감사 속도한스경제 · Sep 22 15:54
-
신테카바이오, 지오비스타와 5억원 규모 AI 항체 최적화 계약 체결
2 more on this story · 2 outlets
- 신테카바이오, 지오비스타와 5억원 규모 AI 치료용 항체 최적화 계약머니투데이 · Sep 11 15:10
- 신테카바이오, 지오비스타와 5억원 규모 ['AI 치료용 항체 최적화' 계약팜뉴스 · Sep 11 16:44